Matthew Baum, MD, PhD, D.Phil PGY-1
Matt holds a B.S. and M.S. in Molecular, Cellular, and Developmental Biology from Yale University; an M.Sc. in Neuroscience from Trinity College, Dublin (where he was a George Mitchell Scholar); a D.Phil. in Neuroethics from Oxford University (where he was a Rhodes Scholar); and an M.D. and Ph.D. (in Neuroscience) from Harvard Medical School. He is the author of the book, “The Neuroethics of Biomarkers: What the Development of Bioprediction Means for Moral Responsibility, Justice, and the Nature of Mental Disorder” (published by Oxford University Press), is a past plenary speaker at the annual meeting of the International Neuroethics Society, and has taught medical ethics at Oxford and Harvard. His neuroscientific work at Harvard focused on the complement cascade, and its regulation, in a synaptic pruning hypothesis of schizophrenia; for this work, he received the Sanger Award graduation prize for research related to psychiatry. During residency, he hopes to develop an integrated scientific, neuroethical, and clinical pursuit of immune-molecule dysfunction in psychosis. Matt also enjoys fermentation (intellectual and actual), a collaborative pursuit that has yielded “Microgli-Ale”, a tribute to the brain cells that engulf synaptic components, and a beer to be “engulfed responsibly”.
Amanda Koire, MD, PhD PGY-1
Amanda holds a B.S. (Molecular Biology) from Pomona College and an M.D. and Ph.D (Quantitative and Computational Biosciences) from Baylor College of Medicine. Her research at Baylor entailed developing computational methods for interpreting rare genetic variants; these methods were used to detect over a dozen experimentally validated novel oncogenes in head and neck cancer and significantly predicted the severity of intellectual disability in patients with autism using only rare variants in genes never before associated with autism. Her work was funded through the Cancer Prevention Research Institute of Texas (CPRIT) predoctoral fellowship and the Robert and Janice McNair M.D./Ph.D. scholarship and resulted in multiple first-author publications. She has been a speaker at the Pacific Symposium on Biocomputing and her cover article in Human Mutation was recognized as one of the journal’s most downloaded papers in its first year after publication. During residency Amanda intends to pursue research in perinatal psychiatry and has been involved in research at BWH studying the psychological impact of COVID19 on pregnant and postpartum women in addition to continuing her work with Texas Children’s Hospital to better optimize postpartum depression screening.
Natalie Feldman, MD PGY-3
I studied Psychology at Harvard College, where I worked as a research assistant in Professor Schacter’s Memory Lab. As a research associate for Dr. Trisha Suppes at the VA Palo Alto Bipolar and Mood Disorder Clinic, I worked on multiple clinical trials at every stage from design and grant-writing through publication, and published a paper as first author in the Journal of Clinical Psychiatry. I was also involved in writing the DSM 5 entry on Depressive Disorders with Short-Duration Hypomania. In medical school, I pursued independent research which was later used in revising the GME training for internal medicine residents at the University of Chicago; I presented that research as a poster at multiple conferences. My proposal for an app for post-partum depression screening was selected as a winner by the University of Chicago App Challenge. My interests include research in women’s mental health and technology in psychiatry.
Heather Burrell Ward, MD PGY-4
Heather is the Chief Resident for Research for the 2020-2021 academic year. She created this innovative Chief Resident position in order to promote scholarly activity across the residency. Heather has a B.A. in Chemistry from Williams College. Her research career began as a clinical research coordinator at the Harvard/MGH Center for Addiction Medicine, where she conducted smoking cessation clinical research studies for individuals with schizophrenia, including the landmark EAGLES trial. She attended Duke University School of Medicine, where she studied the role of tobacco use in the development of first episode psychosis. In the Research Track, she has continued to study tobacco use and psychosis under the mentorship of Roscoe Brady, MD, PhD, Mark Halko, PhD, Amy Janes, PhD, and Lauren Moran, MD. She seeks to understand the biological basis of nicotine dependence in schizophrenia by using functional neuroimaging and neuromodulation. She has developed an expertise in TMS for substance use and designed her own independent research study of TMS for opioid use disorder, which is currently open to enrollment. During residency, she has published numerous first author papers, presented her research findings at national conferences, and served as an NIH grant reviewer. She serves as an Assistant Editor for the Harvard Review of Psychiatry. She received the Early Career Investigator Award at the 2019 American Academy of Addiction Psychiatry Annual Meeting. She is a 2019-2021 APA Leadership Fellow and serves on the APA Council for Research, Council on Addiction Psychiatry, and Tobacco Workgroup. This year, she was selected for the APA Research Colloquium for Junior Investigators.